Abstract Background Fluoroquinolone-resistant Salmonella spp was classified by the WHO as a high priority pathogen due to its increasing resistance and high burden of infection, especially in low- and middle-income countries. This study describes the clinical and microbiological characteristics, comorbidities, and outcomes of patients with salmonellosis assisted in a teaching hospital.Origin of the salmonella samplesSalmonella Serotypes i Methods We conducted a retrospective observational study including patients with a Salmonella spp. positive culture from April 12, 2021, to April 15, 2025. Antimicrobial susceptibility and resistance mechanisms were extracted from microbiology reports. Descriptive statistics and bivariate analysis were used to assess associations between clinical variables and mortality. Results We included 44 isolates from 43 patients with a mean age of 41.3 ± 29.2 years (51.2% males). Mortality admission rate was 7/39 (17.9%). All deceased patients had positive blood cultures (7/23; 30.4%; p 0.05) with a fluoroquinolone-resistant isolate. The most common comorbidities were hypertension (17/43), diabetes (7/43), neoplasia (7/43), and sickle cell disease (3/43) (2 of them had osteomyelitis). 39 of the Salmonella spp. isolates were not classified, 4 corresponded to non-typhoidal Salmonella (2 group B and 2 group C) and 1 was a Salmonella typhi. These isolates were cultured from blood (23), stool (9), skin or tissue (7), urine (3), and pleura (1). The non-susceptibility rate (intermediate or resistant) for ciprofloxacin was 92.7% (38/41), ceftriaxone 6.8% (3/44), cefepime 6.8% (3/44), and trimethoprim-sulfamethoxazole 4/21(19%). 3 isolates had a ESBL phenotype. Clinical presentations included Gastroenteritis (16/44) in which 7 only had blood culture positive, and 9 feces culture, skin and soft tissue infection (8/44), febrile syndrome (4/44) and community acquired pneumonia (5/44). Conclusion This study highlights the impact of quinolone-resistant salmonella in low-medium income countries. There is a high mortality rate in hospitalized patients with salmonellosis, particularly in those with positive blood cultures, where fluroquinolones no longer represent an effective treatment option. We emphasize the need for rational antibiotic use and continuous surveillance to preserve available options. Disclosures Rita A. Rojas-Fermín, MD, GSK: Honoraria
Cruz-Abad et al. (Thu,) studied this question.